ADHD, methylphenidate response, EEG, DNA, CANTAB, spatial span, spatial working memory, stop-task, CPT, theta/beta ratio
Conditions
Interventions
Methylphenidate 10 mg.
Sponsors
Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Eligibility
Inclusion criteria
Inclusion criteria: 1. Diagnosed with ADHD combined type (no primary diagnoses of attention deficit) according to DSM IV criteria (DSM IV, APA 1994); 2. They have (no history of) anxiety disorder, depression, tics, psychosis or autism; 3. Their age is ranged between 7 and 12; 4. IQ is above 75; 5. They are free from psychoactive medication; 6. They are free from methylphenidate at least 48 hours before testing; 7. They have no known cardiovascular disease; 8. Normal static binocular acuity, corrected or uncorrected; 9. Written informed consent from the parents.
Exclusion criteria
Exclusion criteria: 1. IQ is below 75; 2. One or more of the following comorbid disorders are diagnosed: anxiety disorder, depression, tics, psychosis or autism; 3. Prior enrolment in the same study; 4. Participation in another clinical trial simultaneously; 5. Familiar with epileptic disorders; 6. Long term usage of methylphenidate (> 3 months).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measure is the absolute and relative power in different frequency bands of the EEG. | — |
Secondary
| Measure | Time frame |
|---|---|
| Event-related potentials in response to the stop-task and CPT, EEG coherence, Scores on the Spatial Span (SSP) task and Spatial Working Memory (SWM) task from the Cambridge Neuropsychological Test Automated Battery (CANTAB), gene polymorphisms of the dopamine D4 receptor (DRD4), dopamine transporter (DAT1), and serotonin transporter (5-HTT), scores on the SNAP-IV. | — |
Contacts
Public ContactA.E. Wester
Utrecht Institute for Pharmaceutical Sciences, Utrecht University
Outcome results
None listed